Amedisys downgraded to Hold from Buy at Jefferies

Jefferies analyst Brian Tanquilut downgraded Amedisys (AMED) to Hold from Buy with a price target of $101, up from $98, citing after the definitive agreement for UnitedHealth (UNH) to acquire the company in a $101 per share all-cash transaction. While a UnitedHealth deal likely garners Federal Trade Commission scrutiny and could push transaction closing to 2024, competing offers are unlikely to the current finalized merger agreement which Amedisys’ board supports, the analyst tells investors in a research note.